Closed Incision Negative Pressure Therapy in Oncoplastic Surgery Prevents Delays to Adjuvant Therapy
- PMID: 37250834
- PMCID: PMC10219713
- DOI: 10.1097/GOX.0000000000005028
Closed Incision Negative Pressure Therapy in Oncoplastic Surgery Prevents Delays to Adjuvant Therapy
Abstract
Breast reductions, including oncoplastic breast surgery (OBS), have high postoperative wound healing complication (WHC) rates, ranging from 17% to 63%, thus posing a potential delay in the onset of adjuvant therapy. Incision management with closed incision negative pressure therapy (ciNPT) effectively reduces postoperative complications in other indications. This retrospective analysis compares postoperative outcomes and delays in adjuvant therapy in patients who received ciNPT on the cancer breast versus standard of care (SOC) after oncoplastic breast reduction and mastopexy post lumpectomy.
Methods: Patient demographics, ciNPT use, postoperative complication rates, and time to adjuvant therapy were analyzed from the records of 150 patients (ciNPT = 29, SOC = 121). Propensity score matching was used to match patients based on age, body mass index, diabetes, tobacco use, and prior breast surgery.
Results: In the matched cohort, the overall complication rate of ciNPT-treated cancerous breasts was 10.3% (3/29) compared with 31% (9/29) in SOC-treated cancerous breasts (P = 0.096). Compared with the SOC-treated cancerous breasts, the ciNPT breasts had lower skin necrosis rates [1/29 (3.4%) versus 6/29 (20.7%); P = 0.091] and dehiscence rates [0/29 (0%) versus 8/29 (27.6%); P = 0.004]. In the unmatched cohort, the total number of ciNPT patients who had a delay in adjuvant therapy was lower compared to the SOC group (0% versus 22.5%, respectively; P = 0.007).
Conclusion: Use of ciNPT following oncoplastic breast reduction effectively lowered postoperative wound healing complication rates and, most importantly, decreased delays to adjuvant therapy.
Copyright © 2023 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The American Society of Plastic Surgeons.
Conflict of interest statement
Dr Sorice-Virk is a consultant for Sientra Inc. Dr Kanchwala is a consultant for Allergan Inc., Axogen Inc., RTI Surgical, Inc., Sientra Inc., and Surgical Innovation Associates Inc. The other authors have no financial interest to declare. Disclosure statements are at the end of this article, following the correspondence information.
References
-
- Piper ML, Esserman LJ, Sbitany H, et al. . Outcomes following oncoplastic reduction mammoplasty: a systematic review. Ann Plast Surg. 2016;76:S222–S226. - PubMed
-
- Chan SW, Cheung PS, Lam SH. Cosmetic outcome and percentage of breast volume excision in oncoplastic breast conserving surgery. World J Surg. 2010;34:1447–1452. - PubMed
-
- Patel K, Bloom J, Nardello S, et al. . An oncoplastic surgery primer: common indications, techniques, and complications in level 1 and 2 volume displacement oncoplastic surgery. Ann Surg Oncol. 2019;26:3063–3070. - PubMed
-
- Chang E, Johnson N, Webber B, et al. . Bilateral reduction mammoplasty in combination with lumpectomy for treatment of breast cancer in patients with macromastia. Am J Surg. 2004;187:647–650; discussion 650. - PubMed
LinkOut - more resources
Full Text Sources